By Ian Ségal December 5, 2024
The current insulin crisis, affecting both humans and pets with diabetes, represents a significant public health challenge. This crisis stems from a combination of reduced insulin production, supply chain disruptions, and escalating prices. Each factor contributes uniquely to the issue, creating a complex web of barriers that hinder access to this life-saving medication. As healthcare practitioners and public health scientists, it is imperative to critically examine these factors and explore potential solutions to mitigate the crisis.
(Image Source: DeGette, 2022)
Reduced Insulin Production: A Biological Bottleneck
The insulin shortage represents a complex and multifactorial challenge driven by a combination of pandemic-related disruptions, systemic production and distribution issues, and biological limitations in endogenous insulin production. The COVID-19 pandemic significantly exacerbated existing shortages, disrupting global healthcare systems and intensifying concerns among individuals dependent on insulin therapy. Research highlights that insulin shortages were especially pronounced in regions like Iran, where pre-pandemic supply issues were already problematic (Peimani et al., 2022). Moreover, lockdown measures further restricted access to insulin, with 58.3% of children with type 1 diabetes experiencing difficulties obtaining their medication (Rochmah et al., 2023). Similar challenges were reported in Jordan, where families resorted to rationing insulin due to supply chain disruptions (Odeh et al., 2020).
Beyond pandemic-related factors, systemic insulin production and distribution challenges have long contributed to the issue. The manufacturing process for insulin is inherently complex, involving intricate post-translational modifications that influence its stability and efficacy (Shukla et al., 2020). Additionally, economic barriers, such as high costs driven by patent protections and regulatory exclusivities, disproportionately affect access in countries like the United States, where insulin prices remain prohibitively high (Olsen, 2023). These financial constraints often result in nonadherence to prescribed insulin regimens, worsening health outcomes for individuals with diabetes.
The reliance on exogenous insulin, particularly for individuals with type 1 diabetes, underscores the critical importance of a stable supply. While alternative therapies, such as islet transplantation, offer potential solutions, these remain limited by donor shortages and the complexities of immune suppression (Thadani et al., 2017; Mou, 2024). This dependency on insulin highlights the urgent need to address systemic inefficiencies in production and distribution to ensure continuous availability for patients.
(Image Source: Brewster, 2023)
Compounding these challenges is the decline in endogenous insulin production, which is closely linked to pancreatic β-cell dysfunction—a hallmark of diabetes pathophysiology. In type 2 diabetes, β-cells experience significant stress due to obesity and insulin resistance, ultimately leading to exhaustion and dedifferentiation, where β-cells lose their ability to secrete insulin effectively (Accili et al., 2016). Mitochondrial dysfunction within β-cells further impairs insulin secretion, with chronic inflammation and oxidative stress exacerbating these effects (Haythorne et al., 2019; Nisr & Affourtit, 2016). The rising prevalence of obesity and metabolic syndrome globally amplifies these issues, emphasizing the need for innovative therapeutic approaches to preserve β-cell function and enhance endogenous insulin production.
Interestingly, similar mechanisms are observed in veterinary diabetes, where obesity and genetic predispositions in pets mirror human β-cell dysfunction and insulin insufficiency. This parallel underscores the broader implications of diabetes management across species, reinforcing the need for a unified approach to addressing the condition.
The ongoing insulin shortage is a multifaceted crisis influenced by pandemic-related disruptions, systemic production challenges, economic barriers, and biological limitations in insulin production. Effective solutions require a comprehensive strategy that includes improving healthcare access, reforming insulin pricing structures, advancing production capabilities, and exploring innovative therapies to address both exogenous and endogenous insulin insufficiencies.
Supply Chain Disruptions: Challenges and Innovations
The insulin supply chain has encountered profound disruptions, with production challenges experienced by key manufacturers such as Eli Lilly and Novo Nordisk underscoring the fragility of this critical sector. These disruptions have been magnified by a confluence of factors, including economic pressures, regulatory transformations, market competition, and logistical complexities, which collectively strain manufacturers' ability to effectively meet global demand.
Eli Lilly and Novo Nordisk, as two of the largest global insulin producers, have recently announced significant reductions in the list prices of their insulin products. This decision reflects the increasing pressure on pharmaceutical companies to address the affordability of diabetes care amidst rising healthcare costs and growing public scrutiny (Dickson et al., 2023). One key regulatory development influencing this move is the elimination of the Medicaid rebate cap in 2024, which previously limited the extent to which mandatory discounts could reduce net sales (Dickson et al., 2023). The removal of this cap is expected to reshape pricing strategies, potentially intensifying competition among manufacturers. This shift may compel companies to reevaluate their production and distribution processes to remain competitive while balancing profitability and accessibility.
Further compounding these challenges is the growing presence of biosimilar insulins in the market, which has become a pivotal factor in enhancing access to affordable diabetes treatments. Biosimilar products, such as Gensulin, have demonstrated their capacity to reduce financial barriers for patients, particularly in low- and middle-income countries where affordability has historically been a significant obstacle (Vencio et al., 2022). The introduction of biosimilars represents a fundamental shift in market dynamics, challenging traditional manufacturers like Eli Lilly and Novo Nordisk to innovate and adapt. Increased competition from biosimilar producers has the potential to disrupt market dominance, prompting established manufacturers to refine their production strategies and ensure that their supply chains can accommodate new competitive pressures (Vencio et al., 2022).
In addition to market competition, broader supply chain vulnerabilities have exacerbated the challenges facing insulin production and distribution. The cold chain logistics required to preserve insulin efficacy remain a critical concern. Studies have highlighted that failures in cold chain management can lead to significant reductions in insulin potency, raising concerns about product integrity and patient safety (Moses et al., 2018; Petersen et al., 2018). Such disruptions not only threaten the availability of insulin but also underscore the need for manufacturers to prioritize robust logistics systems. In response, companies are increasingly reassessing their supply chain strategies, investing in advanced monitoring technologies and infrastructure to ensure the consistent delivery of high-quality insulin (Connery & Martin, 2018).
The COVID-19 pandemic has further exacerbated the complexities of the insulin supply chain. The global health crisis has created a dual challenge for manufacturers, with heightened demand for diabetes management products coinciding with significant disruptions to production capabilities and logistics networks (Lexchin, 2023). These pressures have resulted in stock shortages and price surges, further straining access to this life-saving medication. To address these challenges, manufacturers such as Eli Lilly and Novo Nordisk have been compelled to innovate their supply chain strategies, incorporating greater flexibility and resilience to meet the evolving demands of the market (Lexchin, 2023). This includes exploring localized production models and leveraging digital technologies to optimize distribution.
(Image Source: Cefalu et al., 2018)
Moreover, the economic pressures on insulin manufacturers are not limited to regulatory changes and market competition. Rising production costs, coupled with the demand for more sustainable practices, have added another layer of complexity to the supply chain. As environmental concerns gain prominence in the pharmaceutical sector, manufacturers are increasingly tasked with balancing cost-efficiency with sustainability goals. Transitioning to greener production methods and minimizing the environmental impact of cold chain logistics will likely become critical priorities in the coming years.
The insulin supply chain is navigating a period of unprecedented disruption driven by a combination of economic, regulatory, competitive, and logistical challenges. The responses from leading manufacturers, including price reductions, biosimilar competition adaptations, and supply chain resilience investments, reflect broader efforts to improve access to diabetes care. However, ensuring the integrity and reliability of the supply chain remains a pressing concern. Addressing these challenges will require sustained innovation and collaboration across the pharmaceutical industry, regulatory bodies, and healthcare systems to ensure that insulin remains accessible, affordable, and effective for patients worldwide.
How Weight Loss Drugs Are Adversely Impacting Insulin Access
The advent of weight reduction drugs such as Ozempic (semaglutide) and tirzepatide has introduced a paradigm shift in the management of type 2 diabetes mellitus (T2DM) and obesity, offering significant metabolic benefits. These medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, have demonstrated remarkable efficacy in improving glycemic control, promoting weight loss, and enhancing insulin sensitivity (Samms et al., 2021). However, from a public health and prevention science perspective, the widespread adoption of these drugs raises critical concerns regarding their potential impact on the production, supply, and accessibility of insulin, a cornerstone therapy for diabetes management in both humans and animals. These concerns highlight the need for a systems-level approach to ensure equitable access to essential diabetes treatments while addressing the broader implications of shifting therapeutic trends.
(Image Source: Goodman, 2023)
Implications for Insulin Demand and Production
The introduction of weight loss medications can potentially reduce the demand for insulin among patients who achieve significant weight loss and improved metabolic health. As Samms et al. (2021) note, GLP-1 receptor agonists like tirzepatide enhance insulin sensitivity and reduce the need for exogenous insulin in many patients with T2DM. While this represents a positive outcome for individual patients, it may have unintended consequences at the population level. Pharmaceutical companies, driven by market forces, may respond to declining insulin demand by scaling back production, potentially disrupting the supply chain. Such adjustments could exacerbate existing disparities in insulin access, particularly for low-income populations who already face significant barriers to obtaining this life-saving medication (Beran et al., 2021). This scenario underscores the importance of maintaining a balanced approach to diabetes care, ensuring that advancements in one area do not inadvertently compromise access to other critical therapies.
From a prevention science perspective, the potential reduction in insulin production raises concerns about the resilience of the global insulin supply chain. Insulin is not only essential for individuals with T2DM but also for those with type 1 diabetes mellitus (T1DM), who are entirely dependent on exogenous insulin for survival. Any disruption in production could disproportionately affect vulnerable populations, including those in low- and middle-income countries (LMICs), where insulin shortages are already a pressing issue (Beran et al., 2021). Policymakers and public health practitioners must anticipate these shifts and implement strategies to safeguard insulin availability, such as incentivizing production, diversifying supply chains, and addressing systemic inequities in diabetes care.
Risks of Insulin Insecurity and Mismanagement
The widespread adoption of weight loss drugs may also contribute to insulin insecurity, a phenomenon characterized by limited access to affordable and reliable insulin supplies. Willner et al. (2020) highlight that many individuals with diabetes, particularly in the United States, resort to underground markets for insulin due to its high cost and limited availability. The introduction of weight loss medications could inadvertently exacerbate this issue by creating a false sense of security among patients and healthcare providers. For instance, patients who experience initial improvements in glycemic control with weight loss drugs may underestimate their ongoing need for insulin, leading to lapses in treatment adherence. This mismanagement could result in severe health complications, including diabetic ketoacidosis (DKA) and long-term organ damage, mainly if patients are unable to access insulin when needed (Litchman et al., 2019).
Furthermore, the financial burden of diabetes management remains a significant challenge for many patients. While weight loss drugs like Ozempic and tirzepatide offer metabolic benefits, their high cost may divert financial resources away from insulin production and accessibility. Xu et al. (2019) emphasize that the rising costs of diabetes care in the United States are already a critical issue, with insulin accounting for a substantial portion of these expenses. The introduction of new, expensive therapies could further strain healthcare systems and exacerbate inequities in diabetes care, particularly for underserved populations. Public health practitioners must advocate for policies prioritizing affordability and accessibility, ensuring that advancements in diabetes treatment do not come at the expense of equitable care.
Broader Implications for Veterinary Medicine
The impact of shifting insulin demand is not limited to human patients; it also extends to veterinary medicine. Pets with diabetes, particularly dogs and cats, rely on insulin for effective disease management. Changes in insulin production and supply dynamics could have significant consequences for veterinary practices, potentially leading to shortages and increased costs for pet owners. As Beran et al. (2021) note, disruptions in the insulin supply chain can have far-reaching effects, highlighting the interconnectedness of human and animal health systems. This underscores the need for a "One Health" approach to diabetes care, which considers the needs of both human and animal populations in the context of broader public health challenges.
Policy and Practice Considerations
The duality of weight reduction drugs—offering significant benefits while posing potential risks—necessitates a proactive and coordinated response from healthcare providers, policymakers, and public health practitioners. To mitigate the risks associated with shifting insulin demand, several strategies should be considered:
Strengthening Insulin Supply Chains: Policymakers must work with pharmaceutical companies to ensure that insulin production remains stable and responsive to global needs. This may involve incentivizing production, diversifying manufacturing sources, and establishing strategic reserves to prevent shortages.
Promoting Equitable Access: Efforts to improve access to weight loss drugs should not overshadow the need to address systemic barriers to insulin accessibility. Subsidies, price caps, and expanded insurance coverage could help reduce the financial burden of diabetes care for low-income populations.
Enhancing Patient Education: Healthcare providers must emphasize the importance of ongoing diabetes management, even for patients who experience improvements with weight loss drugs. Clear communication about the potential risks of discontinuing insulin therapy is essential to prevent adverse health outcomes.
Integrating a One Health Perspective: Veterinary and human healthcare systems should collaborate to address shared challenges in diabetes management, including insulin supply and affordability. This approach recognizes the interconnectedness of human and animal health and promotes holistic solutions to complex public health issues.
Weight reduction drugs like Ozempic and tirzepatide represent a significant advancement in managing T2DM and obesity, offering substantial metabolic benefits for many patients. However, their widespread adoption also poses potential risks to the production, supply, and accessibility of insulin, a critical therapy for diabetes management in both humans and animals. These challenges highlight the need for a systems-level approach to diabetes care that balances new therapies' benefits with the imperative to ensure equitable access to essential treatments. By addressing these issues proactively, public health practitioners and policymakers can help mitigate the unintended consequences of therapeutic innovation, ensuring that the needs of all diabetes patients are met.
Rising Prices: A Barrier to Access
The escalating cost of insulin is one of the most pressing issues in the current crisis. Insulin prices have risen dramatically over the past two decades, with some formulations becoming unaffordable for many patients. This trend is driven by a combination of factors, including high research and development costs, limited market competition, and complex pricing structures involving manufacturers, wholesalers, and insurers (Haji, 2023).
(Image Source: Cardiometabolic Health Congress, 2022)
For individuals with diabetes, the financial burden of insulin can be devastating. Studies have shown that some patients resort to rationing their insulin, a dangerous practice that increases the risk of acute complications such as diabetic ketoacidosis and long-term complications like cardiovascular disease. The impact is similarly severe for pet owners managing diabetes in their animals, as the cost of veterinary insulin and associated care can be prohibitive.
Addressing the issue of rising insulin prices requires systemic reforms. Policymakers must consider implementing price caps, promoting the development of biosimilar insulin products, and increasing transparency in the pharmaceutical supply chain. Additionally, public health campaigns should focus on raising awareness about patient assistance programs and other resources that can help alleviate the financial burden of insulin.
A Path Forward: Comprehensive Solutions for a Complex Crisis
The insulin crisis is a multifaceted problem that demands a comprehensive and collaborative approach. From a public health perspective, the following strategies are essential:
Enhancing Insulin Production: Advances in biotechnology, such as stem cell therapy and gene editing, hold promise for restoring β-cell function and increasing endogenous insulin production. Additionally, research into alternative insulin delivery methods, such as oral or implantable systems, could reduce the reliance on injectable insulin.
Strengthening Supply Chains: Building resilient and adaptive supply chains is critical to ensuring the consistent availability of insulin. This includes investing in local manufacturing capabilities, adopting blockchain technology for supply chain monitoring, and establishing emergency stockpiles to buffer against disruptions.
Addressing Affordability: Policymakers must prioritize affordability by regulating insulin prices, encouraging the production of biosimilars, and fostering competition within the pharmaceutical industry. International cooperation is also necessary to address pricing disparities between countries.
Preventing Diabetes: Finally, prevention is a cornerstone of any long-term solution to the insulin crisis. Public health initiatives should focus on addressing the root causes of diabetes, such as obesity and sedentary lifestyles, through education, community-based interventions, and policy changes that promote healthier environments.
(Image Source: Tucker, 2024)
The insulin crisis represents a significant challenge for global health systems, but it is not insurmountable. By addressing the biological, logistical, and economic factors driving this crisis, we can ensure that insulin remains accessible and affordable for all who need it. As healthcare practitioners and public health scientists, we must advocate for these solutions and work towards a future where no one is denied access to life-saving medication.
Resilience and Innovation Amid the Insulin Crisis
The insulin crisis underscores a formidable public health challenge reverberating across human and veterinary healthcare systems, touching lives globally. Nevertheless, within this complex crisis lies an opportunity for collective action, innovative solutions, and systemic transformation that can ultimately ensure equitable access to this life-saving medication.
The ongoing efforts to address the crisis—from the development of biosimilar insulin and supply chain fortification to the introduction of regulatory reforms—demonstrate the capacity for resilience in the face of adversity. Pharmaceutical companies reducing list prices and adopting sustainable practices, governments exploring price regulations, and the emergence of localized insulin production models collectively signal progress toward a more inclusive healthcare paradigm. These steps are reminders that change, while incremental, is possible through sustained advocacy, interdisciplinary collaboration, and the persistent pursuit of equity.
(Image Source: Alltech, 2020)
Public health practitioners, prevention scientists, and policymakers have an essential role in turning this moment of crisis into a turning point for diabetes care. Strengthening prevention strategies to reduce the burden of diabetes, integrating advanced technologies to secure supply chains, and fostering a "One Health" approach that bridges human and veterinary healthcare are critical pathways forward. These efforts address immediate challenges and lay the groundwork for a more robust, compassionate, and accessible healthcare system.
Most importantly, the resilience and determination of patients, families, and communities facing diabetes inspire hope. Their voices drive the call for change, ensuring that the human and animal lives dependent on insulin are not forgotten amid competing healthcare priorities. The collective response to the insulin crisis exemplifies the potential to transform a fragmented system into one that prioritizes life, equity, and dignity for all.
With innovation, advocacy, and collaboration, the vision of a world where no one—human or animal—faces barriers to life-saving diabetes care is not just aspirational but achievable. As we confront the challenges of the insulin crisis, we do so with the conviction that brighter days lie ahead for those impacted by diabetes, fueled by science, compassion, and the unwavering commitment to health equity.
References
Accili, D., Talchai, S., Kim-Muller, J., Cinti, F., Ishida, E., Ordelheide, A., Kuo, T., Fan, J., & Son, J. (2016). When β‐cells fail: lessons from dedifferentiation. Diabetes Obesity and Metabolism, 18(S1), 117-122. https://doi.org/10.1111/dom.12723
Alarcon, C., Boland, B., Uchizono, Y., Moore, P., Peterson, B., Rajan, S., Rhodes, O., Noske, A., Haataja, L., Arvan, P., Marsh, B., Austin, J., & Rhodes, C. Pancreatic β-cell adaptive plasticity in obesity increases insulin production but adversely affects secretory function. Diabetes, 1 February 2016; 65 (2): 438–450. https://doi.org/10.2337/db15-0792
Alarcón, C., Boland, B., Uchizono, Y., Moore, P., Peterson, B., Rajan, S., … & Rhodes, C. (2015). Pancreatic β-cell adaptive plasticity in obesity increases insulin production but adversely affects secretory function. Diabetes, 65(2), 438-450. https://doi.org/10.2337/db15-0792
Alltech. (2020, March 17). Dr. Ronan Power – insulin innovation: A revolution in the treatment of diabetes. Alltech. https://www.alltech.com/podcast/dr-ronan-power-insulin-innovation-revolution-treatment-diabetes
Beran, D., Lazo-Porras, M., Camille, M., & Mbanya, J. (2021). A global perspective on the issue of access to insulin. Diabetologia, 64(5), 954-962. https://doi.org/10.1007/s00125-020-05375-2
Boston Scientific Corporation. (n.d.). What is type 1 diabetes? PainScale. https://www.painscale.com/article/what-is-type-1-diabetes
Brewster, C. (2023, November 27). Diabetes mellitus: What a diagnosis means for your health. ProVention Health Foundation. https://www.proventionhealth.org/diabetes-mellitus-what-a-diagnosis-means-for-your-health/
Cardiometabolic Health Congress. (2022, April 23). The price of insulin: The real cost of diabetes. Cardiometabolic Health Congress. https://www.cardiometabolichealth.org/the-price-of-insulin-what-diabetes-is-costing-the-u-s/
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., & Yatvin, A. L. (2018). Insulin access and affordability working group: Conclusions and recommendations. Diabetes Care, 41(6), 1299–1311. https://doi.org/10.2337/dci18-0019
Connery, A. and Martin, S. (2018). Lilly calls into question the validity of published insulin concentration results. Journal of Diabetes Science and Technology, 12(4), 892-893. https://doi.org/10.1177/1932296818762502
DeGette, D. (2022, July 28). Price of Insulin. Congresswoman Diana DeGette. https://degette.house.gov/issues/price-insulin
Dickson, S., Gabriel, N., Gellad, W., & Hernandez, I. (2023). Assessment of commercial and mandatory discounts in the gross-to-net bubble for the top insulin products from 2012 to 2019. JAMA Network Open, 6(6), e2318145. https://doi.org/10.1001/jamanetworkopen.2023.18145
Goodman, B. (2023, October 5). Researchers link popular weight loss drugs to serious digestive problems for “hundreds of thousands” worldwide. CNN. https://www.cnn.com/2023/10/05/health/weight-loss-drugs-serious-digestive-problems-study/index.html
Haji, M. (2023). Role of technology in the performance measure of insulin cold chains. J Diabetes Treat, 08: 10116. DOI: https://doi.org/10.29011/2574-7568.010116
Haythorne, E., Rohm, M., van de Bunt, M., Brereton, M. F., Tarasov, A. I., Blacker, T. S., Sachse, G., Silva dos Santos, M., Exposito, R. T., Davis, S., Baba, O., Fischer, R., Duchen, M. R., Rorsman, P., MacRae, J. I., & Ashcroft, F. M. (2019). Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-10189-x
Lexchin, J. (2023). Semaglutide: a new drug for the treatment of obesity. Drug and Therapeutics Bulletin, 61(12), 182-188. https://doi.org/10.1136/dtb.2023.000007
Litchman, M., Oser, T., Wawrzynski, S., Walker, H., & Oser, S. (2019). The underground exchange of diabetes medications and supplies: donating, trading, and borrowing, oh my! Journal of Diabetes Science and Technology, 14(6), 1000-1009. https://doi.org/10.1177/1932296819888215
Moses, A., Bjerrum, J., Hach, M., Wæhrens, L., & Toft, A. (2018). Concentrations of intact insulin concur with FDA and EMA standards when measured by HPLC in different parts of the distribution cold chain. Journal of Diabetes Science and Technology, 13(1), 55-59. https://doi.org/10.1177/1932296818783783
Nazari, A., Sadegheih, A., & Tehrani, R. (2022). Eliminating bullwhip effect in supply chain stock systems using smart controllers. International Journal of Health Sciences, 6703-6722. https://doi.org/10.53730/ijhs.v6ns5.10323
Nisr, R. B., & Affourtit, C. (2016). Palmitate-induced changes in energy demand cause reallocation of ATP supply in rat and human skeletal muscle cells. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1857(9), 1403–1411. https://doi.org/10.1016/j.bbabio.2016.04.286
Petersen, M., Hirsch, I., Skyler, J., Ostlund, R., & Cefalu, W. (2018). In response to carter and heinemann: insulin concentration in vials randomly purchased in pharmacies in the united states: considerable loss in the cold supply chain. Journal of Diabetes Science and Technology, 12(4), 890-891. https://doi.org/10.1177/1932296818761972
Rohli, K., Boyer, C., Blom, S., & Stephens, S. (2022). Nutrient regulation of pancreatic islet β-cell secretory capacity and insulin production. Biomolecules, 12(2), 335. https://doi.org/10.3390/biom12020335
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., Furber, E. P. S., Ruan, X., O’Farrell, L. S., Long, A. M., Dogra, M., Willency, J. A., Lin, Y., Ding, L., Cheng, C. C., … Roell, W. C. (2021). GIPR agonism mediates weight-independent insulin sensitization by Tirzepatide in obese mice. Journal of Clinical Investigation, 131(12). https://doi.org/10.1172/jci146353
Tucker, R. (2024, August 15). Daily insulin use increases cancer risk in type 1 diabetics. Hospital Pharmacy Europe. https://hospitalpharmacyeurope.com/clinical-zones/oncology/daily-insulin-use-increases-cancer-risk-in-type-1-diabetics/
Vencio, S., Caiado‐Vencio, R., Caixeta, L. F., Masierek, M., Mlynarski, W., Drzewoski, J., & Gregory, J. M. (2022). A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication. Diabetes, Obesity and Metabolism, 24(8), 1544–1552. https://doi.org/10.1111/dom.14724
Willner, S., Whittemore, R., & Keene, D. (2020). “life or death”: experiences of insulin insecurity among adults with type 1 diabetes in the United States. SSM - Population Health, 11, 100624. https://doi.org/10.1016/j.ssmph.2020.100624
Xu, Y., Pilla, S., Alexander, G., & Murimi, I. (2019). Use of non-insulin diabetes medicines after insulin initiation: a retrospective cohort study. Plos One, 14(2), e0211820. https://doi.org/10.1371/journal.pone.0211820
Comments